Sugi Predict

Sugi Predict / Compounds / SCHEMBL2827416

SCHEMBL2827416

SCHEMBL2827416

COC(=O)C12CCC(N)(CC1)C2

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ CHRM1 P11229 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ HSD11B1 P28845 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CYP4F2 P78329 1/20 0.32
▸ CYP4A11 Q02928 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19837689 0.98 NPSR1 (0.36) NPSR1LMNACHRM1ADORA2AADORA1
SCHEMBL10151700 0.92 NPSR1 (0.37) NPSR1LMNACHRM1ADORA2AADORA1
SCHEMBL21618356 0.91 NPSR1 (0.38) NPSR1LMNACHRM1ADORA2AADORA1
SCHEMBL705019 0.91 NPSR1 (0.40) NPSR1LMNACHRM1ADORA2AADORA1
Hydrochloric Acid SCHEMBL27221720 0.89 NPSR1 (0.36) NPSR1LMNACHRM1ADORA2AADORA1
Hydrochloric Acid SCHEMBL1932989 0.88 NPSR1 (0.39) NPSR1LMNACHRM1ADORA2AADORA1
Bromide SCHEMBL9989922 0.88 NPSR1 (0.39) NPSR1LMNACHRM1ADORA2AADORA1
SCHEMBL1537011 0.85 NPSR1 (0.43) NPSR1LMNACHRM1ADORA2AADORA1
SCHEMBL16875246 0.85 NPSR1 (0.43) NPSR1LMNACHRM1ADORA2AADORA1
SCHEMBL19766520 0.83 NPSR1 (0.37) NPSR1LMNAMEN1KMT2ACYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680607-A1 BICYCLIC UREAS AS KINASE INHIBITORS Incyte Corporation (US) 2026-01-21 — — EP disclosed
US-12509444-B2 Compounds and methods for CD73 modulation and indications therefor PLEXXIKON INC. (US) 2025-12-30 — — US disclosed
US-20250179023-A1 HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2025-06-05 — — US disclosed
EP-4559908-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF S2CBio Inc. (KR) 2025-05-28 — — EP disclosed
EP-4491617-A1 HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2025-01-15 — — EP disclosed
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2024-09-26 — — US disclosed
WO-2024191996-A1 BICYCLIC UREAS AS KINASE INHIBITORS INCYTE CORPORATION (US) 2024-09-19 — — WO disclosed
WO-2024175043-A1 PYRIDOPYRIMIDINE DERIVATIVE AND USE THEREOF 广东东阳光药业股份有限公司 2024-08-29 — — WO disclosed
CN-118382617-A Full-symmetrical biphenyl derivative and preparation method and application thereof 上海和誉生物医药科技有限公司 2024-07-23 — — CN disclosed
WO-2024058617-A1 ANTIVIRAL USE OF HETEROARYL DERIVATIVE COMPOUND 일동제약(주) 2024-03-21 — — WO disclosed
US-9550798-B2 Compounds that are S1P modulating agents and/or ATX modulating agents BIOGEN MA INC. (US) 2017-01-24 — — US disclosed
US-20150203515-A1 COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS BIOGEN MA, INC. 2015-07-23 — — US disclosed
US-8507493-B2 Amide and amidine derivatives and uses thereof ABBVIE INC. (US) 2013-08-13 — — US disclosed
US-8507493-B2 Amide and amidine derivatives and uses thereof ABBVIE INC. (US) 2013-08-13 — — US disclosed
US-8507493-B2 Amide and amidine derivatives and uses thereof ABBVIE INC. (US) 2013-08-13 — — US disclosed
EP-2243479-A2 Novel amide and amidine derivates and uses thereof Abbott Laboratories (US) 2010-10-27 — — EP disclosed
US-20100267738-A1 NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF ABBOTT LABORATORIES (US) 2010-10-21 — — US disclosed
US-20100267738-A1 NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF ABBOTT LABORATORIES (US) 2010-10-21 — — US disclosed
US-20100267738-A1 NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF ABBOTT LABORATORIES (US) 2010-10-21 — — US disclosed
WO-2006128184-A2 PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS ALANTOS-PHARMACEUTICALS, INC. (US) 2006-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267738-A1 NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF HSD11B2, HSD11B1, HSD17B2 NPSR1 912/4885LMNA 3575/4885CHRM1 2748/4885
US-12509444-B2 Compounds and methods for CD73 modulation and indications therefor ENTPD5, ADORA1, ADORA2A NPSR1 436/4885LMNA 1484/4885CHRM1 429/4885
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors JAK2, UCK2, ULK2 NPSR1 4292/4885LMNA 3304/4885CHRM1 4595/4885
US-20250179023-A1 HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF CD274, PDCD1, PDCD1LG2 NPSR1 3767/4885LMNA 2980/4885CHRM1 3984/4885
US-20150203515-A1 COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS ENPP2, S1PR1, S1PR2 NPSR1 85/4885LMNA 2135/4885CHRM1 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.